home / stock / omga / omga quote
Last: | $2.58 |
---|---|
Change Percent: | -2.54% |
Open: | $2.83 |
Close: | $2.58 |
High: | $3 |
Low: | $2.56 |
Volume: | 394,181 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.58 | $2.83 | $2.58 | $3 | $2.56 | 394,181 | 05-03-2024 |
$2.76 | $2.64 | $2.76 | $2.825 | $2.46 | 695,794 | 05-02-2024 |
$2.48 | $2.25 | $2.48 | $2.59 | $2.25 | 410,403 | 05-01-2024 |
$2.23 | $2.31 | $2.23 | $2.36 | $2.22 | 187,178 | 04-30-2024 |
$2.29 | $2.29 | $2.29 | $2.3562 | $2.26 | 200,712 | 04-29-2024 |
$2.27 | $2.35 | $2.27 | $2.4 | $2.26 | 257,466 | 04-26-2024 |
$2.35 | $2.28 | $2.35 | $2.37 | $2.2001 | 250,249 | 04-25-2024 |
$2.33 | $2.35 | $2.33 | $2.365 | $2.26 | 196,326 | 04-24-2024 |
$2.34 | $2.39 | $2.34 | $2.5399 | $2.32 | 301,171 | 04-23-2024 |
$2.39 | $2.43 | $2.39 | $2.505 | $2.38 | 193,038 | 04-22-2024 |
$2.4 | $2.4 | $2.4 | $2.45 | $2.3409 | 401,872 | 04-19-2024 |
$2.42 | $2.57 | $2.42 | $2.57 | $2.39 | 364,181 | 04-18-2024 |
$2.555 | $2.39 | $2.555 | $2.62 | $2.39 | 387,441 | 04-17-2024 |
$2.41 | $2.45 | $2.41 | $2.45 | $2.26 | 448,455 | 04-16-2024 |
$2.515 | $2.69 | $2.515 | $2.69 | $2.51 | 226,166 | 04-15-2024 |
$2.675 | $2.94 | $2.675 | $2.95 | $2.66 | 252,994 | 04-12-2024 |
$2.96 | $3 | $2.96 | $3 | $2.9 | 191,408 | 04-11-2024 |
$3.01 | $3.01 | $3.01 | $3.015 | $2.9 | 379,951 | 04-10-2024 |
$3.02 | $3.15 | $3.02 | $3.16 | $2.98 | 362,285 | 04-09-2024 |
$3.09 | $3.04 | $3.09 | $3.23 | $2.95 | 477,545 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Omega Therapeutics Inc. Company Name:
OMGA Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pi...
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the America...
MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resi...